ClinicalTrials.gg
CompletedNCT01014247Updated Jun 3, 2013

Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation

A Phase 1 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Placebo in QTc Evaluation and Electrocardiography, sponsored by Bayer. Completed at 6 sites in 4 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-03.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of this study is to investigate the effect of moxifloxacin on the QT interval in order to gain information on the validity of results that will be collected during another clinical study testing riociguat in patients with pulmonary arterial hypertension (PATENT-1 study).

02

Conditions studied

  • QTc Evaluation
  • Electrocardiography

Keywords

  • Moxifloxacin
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy volunteers
  • Age 18-75 years - Normal Exclusion Criteria:
  • Abnormal ECG - Intolerance to fluorochinolones
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

  • Placebo comparator
    Arm 2

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. QTc interval at 3 hours

    Time frame: Day 1 of treatment period 1 and 2

Secondary outcomes

  1. Safety variables

    Adverse events, clinical laboratory, vital signs, ECG findings

    Time frame: Up to last visit of follow up

  2. Pharmacokinetic parameters

    Cmax, Cmax,norm, tmax

    Time frame: On different time points

07

Study locations

6 sites
  • Melbourne, Victoria 3004, Australia
  • Gießen, Hessen 35392, Germany
  • Dresden, Sachsen 01307, Germany
  • Singapore, 119228, Singapore
  • Singapore, 168752, Singapore
  • London, W12 0HS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2009
First posted
Nov 16, 2009
Start
Nov 2009
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Last update
Jun 3, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01014247
Lead sponsor
Bayer
First posted
Nov 16, 2009
Start date
Nov 2009
Primary completion
Jun 2010
Completion
Jun 2010
Last update
Jun 3, 2013

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion